Coherus Oncology, Inc. (CHRS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -158.69M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 15.82M USD | Cost of Goods and Services Sold |
| Research and development | 101.21M USD | Research and Development Expense |
| Selling, general and administration | 92.60M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-158.69M | (m) | $15.82M | $101.21M | $92.60M | (m) |
| 2026-03-31 | $-171.85M | (m) | $14.97M | $106.08M | $97.68M | (m) |
| 2025-12-31 | $-181.13M | (m) | $13.81M | $108.89M | $100.60M | (m) |
| 2025-09-30 | $-92.65M | (m) | $121.34M | $100.18M | $148.86M | (m) |
| 2025-06-30 | $-95.17M | (m) | $120.35M | $94.98M | $152.06M | (m) |
| 2025-03-31 | $-89.31M | (m) | $118.77M | $89.27M | $153.53M | (m) |
| 2024-12-31 | $-111.67M | (m) | $117.55M | $93.34M | $167.74M | (m) |
| 2024-09-30 | $-138.33M | (m) | $168.26M | $98.47M | $175.94M | (m) |
| 2024-06-30 | $-163.94M | (m) | $180.22M | $102.44M | $189.41M | (m) |
| 2024-03-31 | $-177.98M | (m) | $176.70M | $103.75M | $199.39M | (m) |
| 2023-12-31 | $-203.20M | (m) | $158.99M | $109.44M | $192.01M | (m) |
| 2023-09-30 | $-185.79M | (m) | $88.63M | $112.09M | $196.14M | (m) |
| 2023-06-30 | $-234.23M | (m) | $91.16M | $132.25M | $192.75M | (m) |
| 2023-03-31 | $-243.70M | (m) | $77.59M | $150.59M | $198.88M | (m) |
| 2022-12-31 | $-256.88M | (m) | $70.08M | $199.36M | $198.48M | (m) |
| 2022-09-30 | $-244.93M | (m) | $67.98M | $221.10M | $194.91M | (m) |
| 2022-06-30 | $-197.27M | (m) | $54.03M | $229.38M | $190.01M | (m) |
| 2022-03-31 | $-177.42M | (m) | $59.45M | $242.53M | $179.07M | (m) |
| 2021-12-31 | $-263.86M | (m) | $57.59M | $363.11M | $169.71M | (m) |
| 2021-09-30 | $-207.89M | (m) | $57.16M | $356.97M | $157.35M | (m) |
| 2021-06-30 | $-141.38M | (m) | $44.88M | $341.74M | $149.41M | (m) |
| 2021-03-31 | $-51.91M | (m) | $38.32M | $313.14M | $143.12M | (m) |
| 2020-12-31 | $156.32M | (m) | $37.67M | $142.76M | $139.08M | (m) |
| 2020-09-30 | $184.93M | (m) | (m) | $133.08M | $137.46M | (m) |
| 2020-06-30 | $203.05M | (m) | (m) | $115.80M | $137.30M | (m) |
| 2020-03-31 | $165.24M | (m) | (m) | $108.51M | $139.70M | (m) |
| 2019-12-31 | $107.77M | $356.07M | (m) | $94.19M | $137.04M | 30.27% |
| 2019-09-30 | $2.23M | (m) | (m) | $85.90M | $134.81M | (m) |
| 2019-06-30 | $-106.58M | (m) | (m) | $95.94M | $128.35M | (m) |
| 2019-03-31 | $-178.98M | (m) | (m) | $103.57M | $110.28M | (m) |
| 2018-12-31 | $-204.42M | $0.00 | (m) | $110.24M | $94.18M | (m) |
| 2018-09-30 | $-190.38M | (m) | (m) | $115.06M | (m) | (m) |
| 2018-06-30 | $-190.02M | (m) | (m) | $126.09M | (m) | (m) |
| 2018-03-31 | $-201.75M | (m) | (m) | $134.07M | (m) | (m) |
| 2017-12-31 | $-232.14M | $1.56M | (m) | $162.39M | (m) | -14918.77% |
| 2017-09-30 | $-259.13M | $2.40M | (m) | $189.91M | (m) | -10797.08% |
| 2017-06-30 | $-117.90M | $165.24M | (m) | $211.86M | (m) | -71.35% |
| 2017-03-31 | $-124.00M | $177.91M | (m) | $242.90M | (m) | -69.70% |
| 2016-12-31 | $-115.93M | $190.11M | (m) | $254.44M | (m) | -60.98% |
| 2016-09-30 | $-94.68M | (m) | (m) | $246.86M | (m) | (m) |
| 2016-06-30 | $-250.51M | $43.79M | (m) | $250.51M | (m) | -572.05% |
| 2016-03-31 | $-246.67M | $36.59M | (m) | $241.91M | (m) | -674.15% |
| 2015-12-31 | $-219.07M | $30.04M | (m) | $213.06M | (m) | -729.23% |
| 2015-09-30 | $-193.42M | (m) | (m) | $188.50M | (m) | (m) |
| 2015-06-30 | $-128.63M | (m) | (m) | $138.77M | (m) | (m) |
| 2015-03-31 | $-87.67M | (m) | (m) | $100.75M | (m) | (m) |
| 2014-12-31 | $-64.68M | $31.11M | (m) | $78.22M | (m) | -207.94% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $10.30M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $5.84M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-35.99M | $2.75M | (m) | $31.28M | (m) | -1308.36% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-38.52M | $1.90M | (m) | $34.89M | (m) | -2028.33% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |